Using scRNA analysis of biopsies from oncogene-defined lung cancers including EGFR mutant and ALK+ cancers, Maynard et al. revealed a transient immunostimulatory effect in lung cancer patients bearing oncogenic RTKs after initial TKI therapy, followed by establishment of an immunosuppressive environment upon progression33. This evidence concerns the gene ALK and lung cancer.